AC-101 vs OD-07656

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: RIPK2 · full Ulcerative Colitis pipeline

AC-101

Developed by Accropeutics (Accro Bioscience)

Phase 2 in Ulcerative ColitisSmall molecule (oral RIPK2 inhibitor)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: November 2027 · NCT07755241 (registry estimate)

No aligned efficacy figure on record for this race.

OD-07656

Developed by Odyssey Therapeutics

Phase 2 in Ulcerative ColitisSmall molecule (oral RIPK2 scaffolding inhibitor)
Weak signal

NCT06206811 · Phase 1 · completed

All participants across every part of this study received OD-07656 itself, with no placebo or control group and only single-blinding of the participant, so there is no comparison group to assess safety findings against; results have not yet been posted.

No aligned efficacy figure on record for this race.

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAC-101OD-07656
Clinical remission (induction)—Not reported—Not reported
Clinical remission (maintenance)—Not reported—Not reported
Clinical response (induction)—Not reported—Not reported
Endoscopic improvement (induction)—Not reported—Not reported
Corticosteroid-free remission (maintenance)—Not reported—Not reported

Clinical remission (induction)

AC-101
—Not reported
OD-07656
—Not reported

Clinical remission (maintenance)

AC-101
—Not reported
OD-07656
—Not reported

Clinical response (induction)

AC-101
—Not reported
OD-07656
—Not reported

Endoscopic improvement (induction)

AC-101
—Not reported
OD-07656
—Not reported

Corticosteroid-free remission (maintenance)

AC-101
—Not reported
OD-07656
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

AC-101: no structured comparison results are available for Ulcerative Colitis.

OD-07656: no structured comparison results are available for Ulcerative Colitis.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AC-101's landscape · OD-07656's landscape